NICHD SERVICES: Multipurpose Prevention Technologies (MPT) DATABASE ACCESS AND MAINTENANCE for Contraceptive Research

NICHD 服务：避孕研究的多用途预防技术 (MPT) 数据库访问和维护

• 批准号: 10942932
• 负责人: BETHANY YOUNG HOLT
• 金额: $ 20.18万
• 依托单位: PUBLIC HEALTH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-27 至 2024-09-26
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10942932
• 关键词: Academia; Address; Anti-Infective Agents; Biotechnology; Collaborations; Communication; Contraceptive Agents; Databases; Development; Discipline; Event; Funding Agency; Funding Opportunities; Future; Government; HIV; Health; Industry; International; Investments; Knowledge; Maintenance; Marketing; Modality; Persons; Prevention; Publications; Research; Research Personnel; Resources; Technology; Travel; United States National Institutes of Health; Update; Vagina; career; clinical development; equity, diversity, and inclusion; interest; lectures; meetings; news; novel; outreach; posters; pre-clinical; product development; research and development; technology development; webinar

The NICHD Contraception Research Branch (CRB) is conducting research related to developing contraceptives technologies with anti-infective properties against pathogens such as HIV, Bacterial Vaginosis, Chlamydia, etc. – Multipurpose Prevention Technologies. This contract is to support facilitating coordination between relevant stakeholders in multipurpose prevention technology (MPT) development, including product developers, funding agencies, regulatory bodies, academic researchers, the media, and the public in a product neutral capacity to aid in the development of novel MPTs. Note: MPTs are products containing multiple preventative functions, most commonly they consist of a contraceptive plus an HIV preventative but can contain other anti-infectives as long as the product has at least two indications. • Knowledge maintenance - Compile and host resources relevant to MPTs including but not limited to: a. An up-to-date database of all MPTs currently under development. b. Current funding opportunities announcements relevant to MPT developers from NIH and other national and international funders. c. Recent news and publications in the field. d. Relevant webinars, lectures, etc. e. Resources for trainees interested in a career in MPT research. f. Resources for product developers on how best to include underrepresented constituencies in MPT research. g. Any other relevant resources that would be of use to stakeholders in MPT development. • Collaboration and information sharing - Maintain and grow a contact list of stakeholders in MPT development including people from government, academia, industry, philanthropy, and funding agencies. - Provide monthly updates to these stakeholders of relevant news, information, publications, etc. relevant to the MPT field. - Organize and host quarterly events (seminar, panel discussion, lecture, etc.) on a topic relevant to stakeholders. One of the four topics must be specifically related to Diversity, Equity, Inclusion, and Accessibility (DEIA) relevant to MPT stakeholders. Topics could include but would not be limited to: a. Addressing vaginal health in MPT development. b. Incorporating end-user input into MPT product development. c. Transitioning a product from pre-clinical to clinical development. d. Regulatory considerations for MPT products. - Act as a communication hub for current and future stakeholders by: a. Facilitating introductions and interactions between current MPT stakeholders, particularly across disciplines. b. Participating in outreach to potential stakeholders (traveling to and presenting posters or talks at relevant meetings, engaging with potential funders about MPTs) • Ongoing assessment of the MPT development field. - At least 1 publication assessing various gaps and barriers in MPT development, including strategies to overcome these issues. Topics could include but would not be limited to: a. DEIA issues relevant to MPT development. b. Encouraging investment from biotech companies into MPT R&D. c. Incorporating end-user input into the product MPT product development pipeline. d. Outlining and overcoming regulatory hurdles to get MPTs to market. e. The unmet need for MPTs and how to meet these needs. f. Novel delivery modalities for MPTs.

国家儿童健康与发展研究所避孕研究分支正在开展与开发具有抗感染特性的避孕技术有关的研究，以对抗艾滋病毒、细菌性阴道病、衣原体等病原体-多用途预防技术。 该合同旨在支持促进多用途预防技术（MPT）开发中相关利益攸关方之间的协调，包括产品开发商，资助机构，监管机构，学术研究人员，媒体和公众，以产品中立的身份帮助开发新型MPT。 注意事项：MPT是含有多种预防功能的产品，最常见的是它们由避孕药和HIV预防药组成，但只要产品至少有两种适应症，就可以含有其他抗感染药物。 ·知识维护 - 编译和托管与MPT相关的资源，包括但不限于： a. 目前正在开发的所有MPT的最新数据库。 B. 目前的资助机会公告相关的MPT开发人员从NIH和其他国家和国际资助者。 C. 该领域的最新新闻和出版物。 D. 相关网络研讨会、讲座等 e. 对MPT研究职业感兴趣的学员资源。 F. 为产品开发人员提供的资源，介绍如何最好地将代表性不足的群体纳入MPT研究。 G. 在MPT开发中对利益相关者有用的任何其他相关资源。 ·协作和信息共享 - 维护并扩大MPT开发利益相关者的联系人列表，包括来自政府、学术界、工业界、慈善界和资助机构的人员。 - 每月向这些利益相关者提供与MPT领域相关的新闻、信息、出版物等的更新。 - 组织和主办季度活动（研讨会、小组讨论、讲座等）一个与利益相关者相关的话题。四个主题之一必须与MPT利益相关者相关的多样性，公平，包容性和可访问性（DEIA）具体相关。主题可包括但不限于： a. 解决MPT发展中的阴道健康问题。 B. 将最终用户的意见纳入MPT产品开发中。 C. 将产品从临床前阶段过渡到临床开发阶段。 D. MPT产品的监管考虑因素。 - 作为当前和未来利益攸关方的沟通中心，通过以下方式： a. 促进当前MPT利益相关者之间的介绍和互动，特别是跨学科。 B. 参与对潜在利益攸关方的外联活动（前往相关会议并在相关会议上展示海报或演讲，与潜在供资者就MPT进行接触） ·对MPT开发领域的持续评估。 - 至少有一份出版物，评估MPT发展中的各种差距和障碍，包括克服这些问题的战略。主题可包括但不限于： a. 与MPT开发相关的DEIA问题。 B. 鼓励生物技术公司投资MPT研发。 C. 将最终用户的输入纳入产品MPT产品开发管道。 D. 概述并克服监管障碍，将MPT推向市场。 e. 对MPT的未满足需求以及如何满足这些需求。 F. MPT的新型递送方式。